

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 December 2008 (18.12.2008)

PCT

(10) International Publication Number
WO 2008/154271 A1

(51) International Patent Classification:
A01N 43/50 (2006.01) *A61K 31/415* (2006.01)

(21) International Application Number:
PCT/US2008/065865

(22) International Filing Date: 5 June 2008 (05.06.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/942,266 6 June 2007 (06.06.2007) US

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, P.O. Box 7929, Philadelphia, Pennsylvania 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PEAT, Andrew, James** [US/US]; c/o GlaxoSmithKline, Corporate Intellectual Property Department, Five Moore Drive, P.O. Box 13398, Research Triangle Park, North Carolina 27709 (US). **SEBAHAR, Paul, Richard** [US/US]; c/o GlaxoSmithKline, Corporate Intellectual Property Department, Five Moore Drive, P.O. Box 13398, Research Triangle Park, North Carolina 27709 (US). **YOUNGMAN, Michael** [US/US]; c/o GlaxoSmithKline, Corporate Intellectual Property Department, Five Moore Drive, P.O. Box 13398, Research Triangle Park, North Carolina 27709 (US). **CHONG, Pek, Yoke** [MY/US]; c/o GlaxoSmithKline, Corporate Intellectual Property Department, Five Moore Drive, P.O. Box 13398, Research Triangle Park, North Carolina 27709 (US). **ZHANG, Huichang** [CN/US]; c/o GlaxoSmithKline, Corporate Intellectual Property Department, Five Moore Drive, P.O. Box 13398, Research Triangle Park, North Carolina 27709 (US).

(74) Agents: **BRINK, Robert, H.** et al.; GlaxoSmithKline, Corporate Intellectual Property Department, Five Moore Drive, P.O. Box 13398, Research Triangle Park, North Carolina 27709 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(54) Title: CHEMICAL COMPOUNDS

(57) Abstract: The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.

WO 2008/154271 A1